Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC

This study is testing whether combining an immunotherapy drug (IBI308), a drug that cuts off blood supply to tumors (bevacizumab), and standard chemotherapy (pemetrexed and carboplatin) before surgery can shrink stage III non-small cell lung cancer enough to make it removable by surgery. **You may be eligible if...** - You have stage III non-small cell lung cancer that currently cannot be removed by surgery - You are 18–74 years old and in good general health - Your cancer does not have specific genetic mutations (EGFR or ALK) - You are able to perform most daily activities (ECOG 0–1) - Your blood counts, liver, and kidney function are within acceptable ranges **You may NOT be eligible if...** - You have active autoimmune disease - You have uncontrolled infections or serious heart or lung conditions - You are pregnant or breastfeeding - You have previously received certain immunotherapy or targeted therapy drugs - You have already received radiation to the chest Talk to your doctor to see if this trial is right for you.